Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
Rhea-AI Summary
Sangamo Therapeutics (OTCQB:SGMO) will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026. The company will host a public conference call at 4:30 p.m. Eastern that will review financial results and provide business updates, with access via online registration, webcast, and replay.
Positive
- None.
Negative
- None.
News Market Reaction – SGMO
In the May 12 session, SGMO gained 12.73%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings results | Positive | -19.7% | Reported FY25 results plus positive Fabry and neurology program milestones. |
| Mar 19 | Earnings call set | Neutral | -2.7% | Scheduled Q4 and full-year 2025 earnings call and webcast logistics. |
| Nov 06 | Earnings results | Positive | -16.3% | Q3 2025 results with detailed Fabry eGFR data and program timelines. |
| Oct 30 | Earnings call set | Neutral | +4.5% | Announced timing and access details for Q3 2025 earnings call. |
| Aug 07 | Earnings results | Positive | -5.3% | Q2 2025 results with positive Fabry data and narrowed net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings results have often been followed by negative moves, while simple earnings call announcements have seen more muted or mixed reactions.
Recent earnings-related news for Sangamo shows a mix of call announcements and full results. Q2 and Q3 2025, and full-year 2025 earnings releases combined positive Fabry disease data, progressing toward a potential BLA, with detailed financials, yet shares generally fell the next day. In contrast, announcements of upcoming earnings calls on Aug 7, 2025 and Mar 19, 2026 saw smaller, mixed price reactions. Today’s Q1 2026 call scheduling fits this pattern of procedural earnings communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its first quarter 2026 financial results after the market closes on Thursday, May 14, 2026.
The company will hold a conference call at 4:30 p.m. Eastern on Thursday, May 14, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.
Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.
A replay will be available following the conference call, accessible under Events.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn.
Investor Relations and Media Inquiries
Louise Wilkie
ir@sangamo.com
media@sangamo.com
